nach oben

07.12.2020 | Prostatakarzinom | Zertifizierte Fortbildung | Ausgabe 12/2020

Optimale Kombinationen von systemischer und lokaler Therapie

Therapie des oligometastasierten Prostatakarzinoms

Zeitschrift:: InFo Hämatologie + Onkologie > Ausgabe 12/2020

Autoren:: Dr. med. Alexandros Papachristofilou, Dr, med. Pirmin Häuptle

Für das oligometastasierte Prostatakarzinom gibt es noch keine allgemeingültige Definition, meist werden Erkrankungen mit geringem Volumen und niedrigem Risiko so bezeichnet. Genauso diffus wie die Benennung ist derzeit noch die Behandlungsstrategie. ...

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Guckenberger M et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1): e18-e28

Fong Y et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-18; discussion 318-21

Kyriakopoulos CE et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080-7

Fizazi K et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-60

Gandaglia G et al. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol. 2015;68(2):325-34

Gundem G et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353-7

Hövels AM et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387-95

Shen G et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43(11):1503-13

Liu L-P et al. Diagnostic Performance of Diffusion-weighted Magnetic Resonance Imaging in Bone Malignancy: Evidence From a Meta-Analysis. Medicine. 2015;94(45):e1998

10.

Perera M et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403-17

11.

Yaxley JW et al. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. J Urol. 2019;201(4):815-20

12.

Flanigan RC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655-9

13.

Mickisch GH et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966-70

14.

Méjean A et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5): 417-27

15.

Tomlinson JS et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575-80

16.

Leyh-Bannurah S-R et al. Local Therapy Improves Survival in Metastatic Prostate Cancer. Eur Urol. 2017;72(1):118-24

17.

Boevé LMS et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Tria. Eur Urol. 2018; https://doi.org/10.1016/j.eururo.2018.09.008

18.

Parker CC et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-66

19.

Ali SA et al. Benefit of prostate radiotherapy for patients with lymph node only < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE "M1|RT comparison." Ann Oncol. 2019;30(suppl_5):Abstr 850PD

20.

gRAMPP-Studie: https://www.martini-klinik.de/fuer-aerzte/studien/studienuebersicht/g-rampp-studie/ (abgerufen am: 16.11.2020)

21.

Ost P et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018;36(5):446-53

22.

Phillips R et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650-9

23.

Hellman S & Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8-10

24.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D. K., & AWMF). Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Langversion 5.1; http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/

25.

Gravis G et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149-58

26.

Sweeney CJ et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-46

27.

James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77

28.

Clarke NW et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992-2003

29.

Vale CL et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2019;17(2):243-56

30.

James ND et al. Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently. Eur Urol Focus. 2019;5(2):119-22

31.

James ND et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377(4):338-51

32.

Fizazi K et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686-700

33.

Hoyle AP et al. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2019;76(6):719-28

34.

Armstrong AJ et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(32):2974-86

35.

Davis ID et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121-31

36.

Chi KN et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13-24

37.

Kinsey EN et al. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. Cancer J. 2020;26(1):64-75

38.

Sathianathen NJ et al. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2020;77(3):365-72

39.

Fizazi K et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(15_suppl):5514

40.

Hussain M et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465-74

41.

Smith MR et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378(15):1408-18

42.

Sternberg CN et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(23):2197-206

43.

Small EJ et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(15_suppl):Abstr 5516

44.

Gillessen S et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77(4):508-47

Titel: Optimale Kombinationen von systemischer und lokaler Therapie
Therapie des oligometastasierten Prostatakarzinoms
Autoren:: Dr. med. Alexandros Papachristofilou
Dr, med. Pirmin Häuptle
Publikationsdatum: 07.12.2020
Schlagwörter: Prostatakarzinom
Prostatakarzinom
Metastasen
Operation von Metastasen
Tumormarker
Computertomographie
Magnetresonanztomographie
Strahlentherapie
Chemotherapie
DOI: https://doi.org/10.1007/s15004-020-8312-0
Verlag: Springer Medizin
Zeitschrift: InFo Hämatologie + Onkologie Interdisziplinäre Fortbildung von Ärzten für Ärzte
Ausgabe 12/2020
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762

Bildnachweise

Springer Medizin

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Magenkarzinom: Immunchemotherapie bewährt sich in der Erstlinie

Wirkt ein JAK1/2-Inhibitor auch gegen Vitiligo?

"Unzeitgebühr" gilt auch, wenn Patienten das Arzt-Handy anrufen

Galenus-Preis und Charity Award 2020

SOD-Mimetikum gegen orale Mukositiden?

Adjuvante Radiotherapie beim Niedrigrisikomammakarzinom